Literature DB >> 17296633

Spirometry in early childhood in cystic fibrosis patients.

Daphna Vilozni1, Lea Bentur, Ori Efrati, Tal Minuskin, Asher Barak, Amir Szeinberg, Hannah Blau, Elie Picard, Eitan Kerem, Yaacov Yahav, Arie Augarten.   

Abstract

BACKGROUND: Spirometry data in cystic fibrosis (CF) patients in early childhood is scarce, and the ability of spirometry to detect airways obstruction is debatable.
OBJECTIVE: To evaluate the ability of spirometry to detect airflow obstruction in CF patients in early childhood.
METHODS: CF children (age range, 2.5 to 6.9 years) in stable clinical condition were recruited from five CF centers. The children performed guided spirometry (SpiroGame; patented by Dr. Vilzone, 2003). Spirometry indices were compared to values of a healthy early childhood population, and were analyzed with relation to age, gender, and clinical parameters (genotype, pancreatic status, and presence of Pseudomonas in sputum or oropharyngeal cultures).
RESULTS: Seventy-six of 93 children tested performed acceptable spirometry. FVC, FEV1, forced expiratory flow in 0.5 s (FEV0.5), and forced expiratory flow at 50% of vital capacity (FEF50) were significantly lower than healthy (z scores, mean +/- SD: - 0.36 +/- 0.58, - 0.36 +/- 0.72, - 1.20 +/- 0.87; and - 1.80 +/- 1.47, respectively; p < 0.01); z scores for FEV1 and FVC were similar over the age ranges studied. However, z scores for FEV0.5 and forced expiratory flow at 25 to 75% of vital capacity were significantly lower in older children compared to younger children (p < 0.001), and a higher proportion of 6-year-old than 3-year-old children had z scores that were > 2 SDs below the mean (65% vs 5%, p < 0.03). Girls demonstrated lower FEF50 than boys (z scores: - 2.42 +/- 1.91 vs - 1.56 +/- 1.23; p < 0.001). Clinical parameters evaluated were not found to influence spirometric indices.
CONCLUSIONS: Spirometry elicited by CF patients in early childhood can serve as an important noninvasive tool for monitoring pulmonary status. FEV0.5 and flow-related volumes might be more sensitive than the traditional FEV1 in detecting and portraying changes in lung function during early childhood.

Entities:  

Mesh:

Year:  2007        PMID: 17296633     DOI: 10.1378/chest.06-1351

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Abnormal Lung Clearance Index in Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Children with Otherwise Normal FEV1.

Authors:  Ajay S Kasi; Choo Phei Wee; Thomas G Keens; Danieli B Salinas
Journal:  Lung       Date:  2019-12-16       Impact factor: 2.584

2.  Early pulmonary disease manifestations in cystic fibrosis mice.

Authors:  Rebecca J Darrah; Anna L Mitchell; Cara K Campanaro; Eric S Barbato; Paul Litman; Abdus Sattar; Craig A Hodges; Mitchell L Drumm; Frank J Jacono
Journal:  J Cyst Fibros       Date:  2016-05-24       Impact factor: 5.482

3.  Clinically useful spirometry in preschool-aged children: evaluation of the 2007 American Thoracic Society Guidelines.

Authors:  Jonathan M Gaffin; Nancy Lichtenberg Shotola; Thomas R Martin; Wanda Phipatanakul
Journal:  J Asthma       Date:  2010-09       Impact factor: 2.515

4.  Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy.

Authors:  Meyer Kattan; Leonard B Bacharier; George T O'Connor; Robyn Cohen; Ronald L Sorkness; Wayne Morgan; Peter J Gergen; Katy F Jaffee; Cynthia M Visness; Robert A Wood; Gordon R Bloomberg; Susan Doyle; Ryan Burton; James E Gern
Journal:  J Allergy Clin Immunol Pract       Date:  2018-02-13

Review 5.  Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review.

Authors:  R Dobra; C Edmondson; D Hughes; I Martin; J C Davies
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 6.  Endpoints for clinical trials in young children with cystic fibrosis.

Authors:  Stephanie D Davis; Alan S Brody; Mary J Emond; Lyndia C Brumback; Margaret Rosenfeld
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

7.  AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations.

Authors:  Rebecca J Darrah; Frank J Jacono; Neha Joshi; Anna L Mitchell; Abdus Sattar; Cara K Campanaro; Paul Litman; Jennifer Frey; David E Nethery; Eric S Barbato; Craig A Hodges; Harriet Corvol; Garry R Cutting; Michael R Knowles; Lisa J Strug; Mitchell L Drumm
Journal:  J Cyst Fibros       Date:  2018-06-22       Impact factor: 5.482

Review 8.  Lung function tests to monitor respiratory disease in preschool children.

Authors:  Valentina Fainardi; Enrico Lombardi
Journal:  Acta Biomed       Date:  2018-06-14

9.  Cardiopulmonary responses to maximal aerobic exercise in patients with cystic fibrosis.

Authors:  Craig A Williams; Kyle C A Wedgwood; Hossein Mohammadi; Katie Prouse; Owen W Tomlinson; Krasimira Tsaneva-Atanasova
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.